SPM 935

Drug Profile

SPM 935

Alternative Names: UF 09200

Latest Information Update: 08 Dec 2004

Price : $50

At a glance

  • Originator University of Freiburg
  • Developer Schwarz Pharma; University of Freiburg
  • Class Neuroprotectants
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Neurological disorders

Most Recent Events

  • 08 Dec 2001 Discontinued - Preclinical for Neurological disorders in Germany (unspecified route)
  • 09 Nov 2000 Preclinical development for Neurological disorders in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top